These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 27080628)

  • 1. Clinical research and methodology: What usage and what hierarchical order for secondary endpoints?
    Laporte S; Diviné M; Girault D;
    Therapie; 2016 Feb; 71(1):27-41. PubMed ID: 27080628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Statistical considerations for testing multiple endpoints in group sequential or adaptive clinical trials.
    Hung HM; Wang SJ; O'Neill R
    J Biopharm Stat; 2007; 17(6):1201-10. PubMed ID: 18027226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints.
    Sugimoto T; Sozu T; Hamasaki T
    Pharm Stat; 2012; 11(2):118-28. PubMed ID: 22415870
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (II): sample size re-estimation.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2041-54. PubMed ID: 22733687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hierarchical testing of multiple endpoints in group-sequential trials.
    Glimm E; Maurer W; Bretz F
    Stat Med; 2010 Jan; 29(2):219-28. PubMed ID: 19827011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive extensions of a two-stage group sequential procedure for testing primary and secondary endpoints (I): unknown correlation between the endpoints.
    Tamhane AC; Wu Y; Mehta CR
    Stat Med; 2012 Aug; 31(19):2027-40. PubMed ID: 22729929
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A note on familywise error rate for a primary and secondary endpoint.
    Proschan MA; Follmann DA
    Biometrics; 2023 Jun; 79(2):1114-1118. PubMed ID: 35355244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sample size determination in superiority clinical trials with multiple co-primary correlated endpoints.
    Sozu T; Sugimoto T; Hamasaki T
    J Biopharm Stat; 2011 Jul; 21(4):650-68. PubMed ID: 21516562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessing additional benefit in noninferiority trials.
    Kieser M; Stucke K
    Biom J; 2016 Jan; 58(1):154-69. PubMed ID: 24979706
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Method of balanced adjustment in testing co-primary endpoints.
    Kordzakhia G; Siddiqui O; Huque MF
    Stat Med; 2010 Aug; 29(19):2055-66. PubMed ID: 20683896
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Challenge of multiple co-primary endpoints: a new approach.
    Chuang-Stein C; Stryszak P; Dmitrienko A; Offen W
    Stat Med; 2007 Mar; 26(6):1181-92. PubMed ID: 16927251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved two-stage group sequential procedures for testing a secondary endpoint after the primary endpoint achieves significance.
    Li H; Wang J; Luo X; Grechko J; Jennison C
    Biom J; 2018 Sep; 60(5):893-902. PubMed ID: 29876964
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design and analysis issues of multiregional clinical trials with different regional primary endpoints.
    Tsou HH; Tsong Y; Chang WJ; Dong X; Hsiao CF
    J Biopharm Stat; 2012 Sep; 22(5):1051-9. PubMed ID: 22946949
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sample size determination in clinical trials with multiple co-primary endpoints including mixed continuous and binary variables.
    Sozu T; Sugimoto T; Hamasaki T
    Biom J; 2012 Sep; 54(5):716-29. PubMed ID: 22829198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Testing non-inferiority and superiority for two endpoints for several treatments with a control.
    Lawrence J
    Pharm Stat; 2011; 10(4):318-24. PubMed ID: 20949636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplicity Adjustment and Sample Size Calculation in Clinical Trials with Multiple Endpoints: An Industry Survey of Current Practices in Japan.
    Sakamaki K; Morita Y; Iba K; Kamiura T; Yoshida S; Ogawa N; Suganami H; Tsuchiya S; Fukimbara S
    Ther Innov Regul Sci; 2020 Sep; 54(5):1097-1105. PubMed ID: 32030692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A consistency-adjusted strategy for accommodating an underpowered primary endpoint.
    Huque MF; Alosh M
    J Biopharm Stat; 2012; 22(1):160-79. PubMed ID: 22204533
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality-of-life as co-primary endpoint in randomized clinical trials in oncology.
    Fiteni F; Pam A; Anota A; Vernerey D; Paget-Bailly S; Westeel V; Bonnetain F
    Expert Rev Anticancer Ther; 2015; 15(8):885-91. PubMed ID: 26027598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of three sample size calculation methods for non-inferiority vaccine trials with multiple continuous co-primary endpoints.
    Yang J; Li J; Wang S; Luo L; Liu P
    Hum Vaccin Immunother; 2019; 15(1):256-263. PubMed ID: 30273507
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical grand rounds: design and analysis of studies with binary- event composite endpoints: guidelines for anesthesia research.
    Mascha EJ; Sessler DI
    Anesth Analg; 2011 Jun; 112(6):1461-71. PubMed ID: 21543784
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.